Switch theme
Sign up to access all valuation multiples
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
2018
36
LTM Revenue $4.8M
Last FY EBITDA -$27.7M
$20.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
HCW Biologics has a last 12-month revenue (LTM) of $4.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, HCW Biologics achieved revenue of $2.6M and an EBITDA of -$27.7M.
HCW Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See HCW Biologics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.8M | XXX | $2.6M | XXX | XXX | XXX |
| Gross Profit | $4.0M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Margin | 83% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$27.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1078% | XXX | XXX | XXX |
| EBIT | -$18.3M | XXX | -$29.0M | XXX | XXX | XXX |
| EBIT Margin | -382% | XXX | -1128% | XXX | XXX | XXX |
| Net Profit | -$18.7M | XXX | -$30.0M | XXX | XXX | XXX |
| Net Margin | -390% | XXX | -1170% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $9.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, HCW Biologics's stock price is $4.
HCW Biologics has current market cap of $7.8M, and EV of $20.6M.
See HCW Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.6M | $7.8M | XXX | XXX | XXX | XXX | $-17.66 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, HCW Biologics has market cap of $7.8M and EV of $20.6M.
HCW Biologics's trades at 8.0x EV/Revenue multiple, and -0.7x EV/EBITDA.
Equity research analysts estimate HCW Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
HCW Biologics has a P/E ratio of -0.4x.
See valuation multiples for HCW Biologics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.8M | XXX | $7.8M | XXX | XXX | XXX |
| EV (current) | $20.6M | XXX | $20.6M | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.4x | XXX | -0.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHCW Biologics's last 12 month revenue growth is 46%
HCW Biologics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.8M for the same period.
HCW Biologics's rule of 40 is -783% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
HCW Biologics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for HCW Biologics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 46% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1078% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -783% | XXX | -1032% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 249% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1165% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
HCW Biologics acquired XXX companies to date.
Last acquisition by HCW Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . HCW Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was HCW Biologics founded? | HCW Biologics was founded in 2018. |
| Where is HCW Biologics headquartered? | HCW Biologics is headquartered in United States of America. |
| How many employees does HCW Biologics have? | As of today, HCW Biologics has 36 employees. |
| Who is the CEO of HCW Biologics? | HCW Biologics's CEO is Dr. Hing C. Wong, PhD. |
| Is HCW Biologics publicy listed? | Yes, HCW Biologics is a public company listed on NAS. |
| What is the stock symbol of HCW Biologics? | HCW Biologics trades under HCWB ticker. |
| When did HCW Biologics go public? | HCW Biologics went public in 2021. |
| Who are competitors of HCW Biologics? | Similar companies to HCW Biologics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of HCW Biologics? | HCW Biologics's current market cap is $7.8M |
| What is the current revenue of HCW Biologics? | HCW Biologics's last 12 months revenue is $4.8M. |
| What is the current revenue growth of HCW Biologics? | HCW Biologics revenue growth (NTM/LTM) is 46%. |
| What is the current EV/Revenue multiple of HCW Biologics? | Current revenue multiple of HCW Biologics is 4.3x. |
| Is HCW Biologics profitable? | Yes, HCW Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
